CerSci Therapeutics

CerSci

Dallas-based Biotech CerSci Acquired by ACADIA Pharmaceutical in $52.5M Deal

by | Aug 25, 2020
CerSci shareholders could net another $887 million in milestones and tiered royalties. The clinical-stage startup, which launched in 2015, is developing a new generation of non-opioid meds to treat acute and chronic pain.
MORE►
Dialectic
Dialectic Therapeutics Plans to Further Cancer Drug Research Using $3M Seed Award
by | Feb 26, 2020
Using innovative new technologies and targeted therapies, the Dallas biotech startup aims to help patients with cancer, give them hope, and prolong their lives.
MORE►
CerSci
Meet the Innovators: Lucas Rodriguez, CEO of CerSci Therapeutics
by | Apr 1, 2019
CerSci's focus is on alleviating human suffering and rescuing society from the ongoing opioid crisis via a pain drug that does not affect the central nervous system.
MORE►
funding
Fueling Disruption:
Local Startups That Got Funding in 2017
Funding rounds brought millions in capital from investors for North Texas startups.
MORE►